National Bank of Canada FI Sells 66,191 Shares of Moderna, Inc. (NASDAQ:MRNA)

National Bank of Canada FI reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 28.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 169,075 shares of the company's stock after selling 66,191 shares during the period. National Bank of Canada FI's holdings in Moderna were worth $7,030,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares during the period. Compass Planning Associates Inc bought a new position in shares of Moderna during the 4th quarter worth $37,000. Venturi Wealth Management LLC increased its holdings in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after acquiring an additional 664 shares during the last quarter. Crowley Wealth Management Inc. bought a new stake in Moderna in the 4th quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after purchasing an additional 389 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several research reports. UBS Group lowered their price target on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Argus cut shares of Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Evercore ISI set a $50.00 price target on Moderna in a report on Friday, February 14th. Berenberg Bank lifted their price target on Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. Finally, Morgan Stanley dropped their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a report on Wednesday. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $58.70.

Remove Ads

Moderna Stock Up 6.9 %

Shares of Moderna stock traded up $1.70 during trading on Friday, hitting $26.20. 10,999,018 shares of the stock traded hands, compared to its average volume of 7,181,061. The stock has a market cap of $10.13 billion, a price-to-earnings ratio of -2.82 and a beta of 2.23. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The firm's fifty day moving average is $31.56 and its 200-day moving average is $41.01.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.